<div id="readability-page-1">We recently published a list of the 8 Best Dividend Leaders to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other best dividend leaders to buy.Investors have long been drawn to dividend stocks due to their financial stability and impressive returns, which have consistently outperformed other asset classes over the years. While these stocks may be underperforming at the moment, their long-term returns make them an attractive choice for investors. This means that building wealth through dividends requires patience, as the rewards accumulate over time rather than delivering instant results. The long-term performance of dividend stocks highlights their importance. According to a report by Hartford Funds, over the past several decades, dividends have been a major contributor to investor returns. Since 1960, reinvested dividends and the power of compounding have accounted for 85% of the cumulative total return of the broader market. The report also mentioned that in the 1940s, 1960s, and 1970s—periods when total returns were below 10%—dividends made a significant contribution to overall returns.Investors often gravitate toward dividend-paying stocks during market downturns or periods of economic uncertainty. Companies with substantial payouts, such as those in utilities and consumer staples, are known for generating consistent earnings regardless of market conditions. However, during market rallies, these stocks typically underperform. This trend has been particularly noticeable since 2020, as mega-tech stocks have frequently driven the market to record highs.Chris O’Keefe, a portfolio manager at Logan Capital Management, suggested that the growing performance gap between the broader market and dividend stocks this year presents an ideal opportunity for investors to consider buying dividend stocks. In addition to O’Keefe, several analysts are urging investors to focus on dividend stocks, citing their favorable outlook. The Dividend Aristocrats Index, which tracks 66 companies that have consistently increased their dividends annually for the past 25 years, has struggled to keep up with the broader market since 2020. Dividend-paying stocks experienced a resurgence in 2022, as recession fears prompted investors to turn to stable sectors like utilities and consumer goods. However, the rebound was short-lived. By 2023, rising interest rates pushed bond and money-market returns higher than dividend yields, leading major companies to adopt a cautious approach and tighten cash reserves amid economic uncertainty. This year, many of the same leading stocks from the Covid era have once again propelled the market to record highs.The Dividend Aristocrats Index has risen nearly 5% since the beginning of 2024, while the broader market has returned 24%. Despite underperforming, dividend stocks remain a preferred choice for investors. A Morningstar report revealed that US exchange-traded funds (ETFs) focused on dividends held nearly $500 billion in investor assets by the fourth quarter of 2024, with additional billions in actively managed equity income funds. These funds have seen inflows this year, though much smaller compared to the $70 billion they attracted in 2022, which was a strong year for dividends.Bank of America analyst Ohsung Kwon believes a resurgence in dividend stocks could be on the horizon. His team anticipates that the companies in the broader market will collectively boost their dividend payouts by 10% in 2025, driven by investor demand for cash. Reflecting this trend, even major tech firms have begun distributing dividends.<div id="attachment_1196019"><img src="https://imageproxy.pbkrs.com/https://imonkey-blog.imgix.net/blog/wp-content/uploads/2023/09/20100407/PFE-insidermonkey-1695218644644.jpg/query-YXV0bz1mb3J0bWF0JmV4cGlyZXM9MTc2NjI3NTIwMCZmaXQ9Y2xpcCZoZWlnaHQ9MjY5JndpZHRoPTQ4MA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="830" height="465" original-src="https://imageproxy.pbkrs.com/https://imonkey-blog.imgix.net/blog/wp-content/uploads/2023/09/20100407/PFE-insidermonkey-1695218644644.jpg/query-YXV0bz1mb3J0bWF0JmV4cGlyZXM9MTc2NjI3NTIwMCZmaXQ9Y2xpcCZoZWlnaHQ9MjY5JndpZHRoPTQ4MA"/>A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution.</div><h3>Our Methodology</h3>For this list, we scanned holdings of First Trust Morningstar Dividend Leaders Index Fund (FDL), which tracks the performance of the 100 highest-yielding stocks with consistent growth in dividends and can maintain their dividends in the future. From this list, we further refined our selection criteria by identifying stocks with a projected upside potential of over 15% based on analyst price targets, as of December 19. The stocks are ranked according to their upside potential. We also considered hedge fund sentiment around each stock using Insider Monkey’s data for Q3 2024.Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).<h3>Pfizer Inc. (NYSE:PFE)</h3>Upside Potential as of December 19: 22.4%Pfizer Inc. (NYSE:PFE) is a New York-based pharmaceutical industry company that specializes in a wide range of medications and vaccines. The company gained significant attention during the pandemic for developing vaccines. However, this recent success, driven by its COVID-19 vaccine and treatment pill, has led some investors to perceive it as a stock that may have peaked. With a sharp decline in vaccine demand, concerns have arisen about potential changes in vaccine policy under the incoming Trump administration, further heightening investor uncertainty. The stock has fallen by over 13% in 2024 so far.Despite concerns, Pfizer Inc. (NYSE:PFE) posted strong earnings in its latest quarter. The company generated $17.7 billion in revenue, marking a notable 32% increase compared to the same period last year. Its Oncology portfolio continued to perform well, with significant contributions from products like Padcev, Xtandi, Lorbrena, and Braftovi/Mektovi. In addition, the company successfully met the heightened demand for Paxlovid during the recent surge in COVID-19 cases.Pfizer Inc. (NYSE:PFE) remains in strong financial health, as evidenced by its solid cash position. In the first nine months of 2024, the company returned $7.1 billion to shareholders through dividends. With a quarterly dividend of $0.42 per share, the stock offers an appealing dividend yield of 6.67% as of December 19. Known for its reliable payouts, the company has consistently increased its dividends for 14 years, making it one of the best dividend leaders on our list.Parnassus Investments highlighted Pfizer Inc. (NYSE:PFE) in its Q1 2024 investor letter. Here is what the firm has to say:<blockquote> “During the quarter, we added new positions in Pfizer Inc. (NYSE:PFE), NICE and Charter Communications. We purchased Pfizer to capture the potential upside from any turnaround following the COVID-induced boom-bust cycle of the last few years. Pfizer’s stock price sank by more than 40% in 2023 as COVID-19 vaccine revenues rolled off, providing an attractive entry point for us. The company completed its acquisition of Seagen, which should strengthen Pfizer’s pipeline in antibody-drug conjugates (ADC). Pfizer also offers an attractive dividend yield.” </blockquote>Of the 900 hedge funds tracked by Insider Monkey at the end of Q3 2024, 80 hedge funds held stakes in Pfizer Inc. (NYSE:PFE), compared with 84 in the previous quarter. These stakes are collectively valued at over $3 billion.Overall, PFE ranks 5th on our list of the best dividend leaders according to analysts. While we acknowledge the potential for PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: Disclosure: None. This article is originally published at Insider Monkey.Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! The whispers are turning into roars. Artificial intelligence isn’t science fiction anymore. It’s the revolution reshaping every industry on the planet. From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards. Here’s why this is the prime moment to jump on the AI bandwagon: Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory. Imagine every sector, from healthcare to finance, infused with superhuman intelligence. We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything. This isn’t a maybe – it’s an inevitability. Early investors will be the ones positioned to ride the wave of this technological tsunami. Ground Floor Opportunity: Remember the early days of the internet? Those who saw the potential of tech giants back then are sitting pretty today. AI is at a similar inflection point. We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon. This is your chance to get in before the rockets take off! Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation. AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries. The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust. As an investor, you want to be on the side of the winners, and AI is the winning ticket. The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI. From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field. This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements. By investing in AI, you’re essentially backing the future. The future is powered by artificial intelligence, and the time to invest is NOW. Don’t be a spectator in this technological revolution. Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation. This isn’t just about making money – it’s about being part of the future. So, buckle up and get ready for the ride of your investment life! Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!) The AI revolution is upon us, and savvy investors stand to make a fortune. But with so many choices, how do you find the hidden gem – the company poised for explosive growth? That’s where our expertise comes in. We’ve got the answer, but there’s a twist… Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap. That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade! Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity. This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors. It’s like having a race car on a go-kart track. They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field. Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel. We want to make sure none of our valued readers miss out on this groundbreaking opportunity! That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%. For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal! Here’s why this is a deal you can’t afford to pass up: • Access to our Detailed Report on this Game-Changing AI Stock:Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential. • 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan. • One free upcoming issue of our 70+ page Quarterly Newsletter:A value of $149 • Bonus Reports:Premium access to members-only fund manager video interviews • Ad-Free Browsing:Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity. • 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked. Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment. Here’s what to do next: 1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29. 2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months. 3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee. Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future! Subscribe Now! No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later! I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries. We’re independently funding today’s broadcast to address something on the mind of every investor in America right now… Should I put my money in Artificial Intelligence? Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin. Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance… But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down. That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet… And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day. He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance. Click to continue reading… </div>

Pfizer Inc. (PFE) is highlighted as one of the best dividend leaders to buy according to Wall Street analysts. Despite recent underperformance compared to the broader market, dividend stocks are favored for their long-term returns and financial stability. Analysts suggest that the current market conditions present a buying opportunity for dividend stocks, with expectations of a 10% increase in dividend payouts by 2025. Pfizer has a projected upside potential of 22.4%, making it an attractive option for investors seeking dividend income.

- The article discusses Pfizer Inc. (NYSE:PFE) in the context of dividend stocks, highlighting its strong earnings and consistent dividend payouts despite recent stock price declines.  
- It notes that while dividend stocks have underperformed compared to the broader market, analysts suggest they remain a solid investment choice, especially during economic uncertainty.  
- Pfizer's dividend yield is appealing at 6.67%, and the company is expected to increase its dividend payouts by 10% in 2025, driven by investor demand for cash.

Pfizer Inc. (PFE) Is Among the Best Dividend Leaders to Buy According to Wall Street Analysts